Quest Diagnostics

Europe

Cancer Research U.K. invests $23.6 million in new major centers

Friday, June 26, 2015 09:16 AM

Cancer Research U.K. has launched Major Centers in Oxford, Manchester and Cambridge, with each receiving $7.7 million to boost their work in personalized cancer medicine and early detection research.

More... »


AveXis gains EMA Orphan designation from for spinal muscular atrophy treatment

Thursday, June 25, 2015 11:02 AM

The EMA has granted Orphan Drug designation to a gene transfer therapeutic currently in clinical development in the U.S. for the treatment of type 1 spinal muscular atrophy (SMA). AveXis, a gene therapy company developing treatments for rare and life-threatening genetic diseases, received Orphan Drug designation for SMA in the U.S. in Oct. 2014.

More... »


Redx Pharma launches third subsidiary, Redx Immunology

Monday, May 18, 2015 01:05 PM

Redx Pharma has launched its third subsidiary, Redx Immunology, which will focus on developing new therapies for disorders of the immune system.

More... »

Alexion Pharmaceuticals expands in Dublin, to add 200 jobs

Monday, May 11, 2015 03:19 PM

Alexion Pharmaceuticals will significantly expand its operations in Ireland by constructing the company's first ever biologics manufacturing facility outside the U.S. This $502.6 million, four-year project, which will be constructed at Alexion's College Park site in Blanchardstown, is expected to create approximately 200 additional full-time jobs on completion, bringing Alexion's total workforce in Ireland to almost 500.

More... »

Study: Clinical trial transparency improving

Thursday, May 7, 2015 12:23 PM

Transparency amongst industry-sponsored clinical trials continues to improve with results of 90% of trials on all new medicines approved by the EMA in 2012 disclosed within a 12-month timeframe, according to an Association of the British Pharmaceutical Industry (ABPI) study.

More... »

EMA tightens rules on 'revolving door' for committee members and experts

Thursday, May 7, 2015 12:21 PM

The EMA has updated its rules on declarations of interests for scientific committee members and experts. The updates further strengthen EMA’s policy by restricting involvement of experts in the scientific assessment of medicines if they plan to take up a job in the pharmaceutical industry. The updates also include a revised guide on how to complete the agency’s declaration of interest form.

More... »

Report: Transparency, cooperation help reduce high prices for new medicines

Friday, March 27, 2015 11:19 AM

As the number of new medicines introduced in Europe rises, governments are finding it increasingly difficult to afford them, according to a comprehensive study released today by the WHO Regional Office for Europe. The study illustrates the challenges for national health systems, with specific examples, and shows that few countries in the WHO European Region have mechanisms in place to evaluate the cost-effectiveness of new drugs; this hampers the value-assessment and decision-making processes.

More... »

Clinicians, researchers and industry collaborate with the 100,000 Genomes Project

Friday, March 27, 2015 11:12 AM

Genomics England has announced a new collaboration as part of the 100,000 Genomes Project to accelerate the development of new diagnostics and treatments for patients. Ten pharma and biotech companies have come together to create the Genomics Expert Network for Enterprises (GENE) Consortium to oversee a year-long industry trial.

More... »

Biomedical Catalyst to award $59M for new research

Thursday, March 26, 2015 03:00 PM

New treatments, diagnostics and medical technologies are set to benefit from an investment of $47 million through the Biomedical Catalyst (BMC)—a partnership between the Medical Research Council (MRC) and Innovate U.K. This MRC and Innovate U.K. funding will be further boosted by over $12 million of investment leveraged from industry, bringing the total investment for this round to $59 million.

More... »

New Innovative Medicines Initiative project launched to combat carbapenem resistance

Wednesday, March 25, 2015 03:15 PM

Eighteen European academic partners and three pharmaceutical companies are launching a new project under the Innovative Medicines Initiative (IMI) funded New Drugs 4 Bad Bugs (ND4BB) program. COMBACTE-CARE (Combating Bacterial resistance in Europe-Carbapenem-Resistance) will bring highly innovative studies and activities related to the treatment of patients with infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). Being very difficult to treat and sometimes deadly, CRE are considered to be one of the most dangerous resistant bacteria in the world. University Medical Center Utrecht is the project’s managing entity.

More... »

`

CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs